CA2586176A1 - Methodes de preparation de composes d'indazole - Google Patents

Methodes de preparation de composes d'indazole Download PDF

Info

Publication number
CA2586176A1
CA2586176A1 CA002586176A CA2586176A CA2586176A1 CA 2586176 A1 CA2586176 A1 CA 2586176A1 CA 002586176 A CA002586176 A CA 002586176A CA 2586176 A CA2586176 A CA 2586176A CA 2586176 A1 CA2586176 A1 CA 2586176A1
Authority
CA
Canada
Prior art keywords
formula
compound
alkyl
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002586176A
Other languages
English (en)
Inventor
Srinivasan Babu
Raymond Dagnino Jr.
Michael Allen Ouellette
Bing Shi
Qingping Tian
Scott Edward Zook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Srinivasan Babu
Raymond Dagnino Jr.
Michael Allen Ouellette
Bing Shi
Qingping Tian
Scott Edward Zook
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Srinivasan Babu, Raymond Dagnino Jr., Michael Allen Ouellette, Bing Shi, Qingping Tian, Scott Edward Zook, Pfizer Inc. filed Critical Srinivasan Babu
Publication of CA2586176A1 publication Critical patent/CA2586176A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
CA002586176A 2004-11-02 2005-10-21 Methodes de preparation de composes d'indazole Abandoned CA2586176A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62457504P 2004-11-02 2004-11-02
US60/624,575 2004-11-02
PCT/IB2005/003300 WO2006048745A1 (fr) 2004-11-02 2005-10-21 Methodes de preparation de composes d'indazole

Publications (1)

Publication Number Publication Date
CA2586176A1 true CA2586176A1 (fr) 2006-05-11

Family

ID=35528034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002586176A Abandoned CA2586176A1 (fr) 2004-11-02 2005-10-21 Methodes de preparation de composes d'indazole

Country Status (15)

Country Link
EP (1) EP1809625A1 (fr)
JP (1) JP2008518901A (fr)
KR (1) KR20070058689A (fr)
CN (1) CN101044138A (fr)
AR (1) AR051753A1 (fr)
AU (1) AU2005300311A1 (fr)
BR (1) BRPI0517921A (fr)
CA (1) CA2586176A1 (fr)
IL (1) IL182096A0 (fr)
MX (1) MX2007003603A (fr)
NO (1) NO20072747L (fr)
RU (1) RU2007114112A (fr)
TW (1) TW200614990A (fr)
WO (1) WO2006048745A1 (fr)
ZA (1) ZA200702317B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
NZ580126A (en) 2007-04-05 2012-03-30 Pfizer Prod Inc Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
WO2009055730A1 (fr) * 2007-10-25 2009-04-30 Genentech, Inc. Procédé de préparation de composés de thiénopyrimidine
EP2163544A1 (fr) * 2008-09-16 2010-03-17 Pfizer, Inc. Méthodes de préparation de composés d' indazole
SG11201400145VA (en) 2011-09-30 2014-03-28 Pfizer Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
KR20140088556A (ko) 2011-11-11 2014-07-10 화이자 인코포레이티드 만성 골수성 백혈병을 치료하기 위한 n-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일설파닐]-벤즈아미드
EP2792360A1 (fr) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
CN103387565B (zh) * 2013-07-29 2014-10-29 苏州明锐医药科技有限公司 阿西替尼的制备方法
CN103570696B (zh) * 2013-11-06 2016-02-24 湖南欧亚生物有限公司 一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用
WO2015067224A1 (fr) 2013-11-08 2015-05-14 Zentiva, K.S. Sels de 6-[2- (méthylcarbamoyl) phénylsulfanyl]-3-e-[2-(pyridin-2-yl) éthanyl]indazole
SG11201605824XA (en) 2014-02-04 2016-08-30 Pfizer Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
ES2647262T3 (es) * 2014-03-31 2017-12-20 Senju Pharmaceutical Co. Ltd Derivado de alquinil indazol y uso del mismo
CN104072484B (zh) * 2014-07-07 2016-07-06 渤海大学 氮-(4-(芳巯基)-1氢-吲唑-3-基)-1-(芳杂环取代)甲基亚胺类化合物及其药学上可接受的盐及其制备方法和应用
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016057931A1 (fr) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluorométhoxylation d'arènes via une migration intramoléculaire du groupe trifluorométhoxy
EP3262073A1 (fr) 2015-02-26 2018-01-03 Merck Patent GmbH Inhibiteurs de pd-1/pd-l1 pour le traitement du cancer
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
IL256245B (en) 2015-06-16 2022-09-01 Merck Patent Gmbh Treatments that combine a pd-l1 antagonist
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
WO2020212253A1 (fr) 2019-04-18 2020-10-22 Synthon B.V. Procédé de préparation d'axitinib, procédé de purification de l'intermédiaire 2-((3-iodo-1h-indazol-6-yl)thio)-n-méthylbenzamide, procédé de purification d'axitinib par l'intermédiaire du sel d'axitinib hcl, forme solide du sel d'axitinib hcl
CN112209861A (zh) * 2019-07-11 2021-01-12 鲁南制药集团股份有限公司 一种阿昔替尼中间体化合物及其制备方法
CN112442010B (zh) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 一类前药化合物及其在治疗癌症方面的应用
CN111440102B (zh) * 2020-04-26 2022-02-15 大连凯飞化学股份有限公司 一种二硫代二苯甲酰胺类化合物的制备方法
WO2023166420A1 (fr) 2022-03-03 2023-09-07 Pfizer Inc. Anticorps multispécifiques et leurs utilisations
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
NZ540340A (en) * 2002-12-19 2007-07-27 Pfizer 2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
WO2004078116A2 (fr) * 2003-03-03 2004-09-16 Array Biopharma, Inc. Inhibiteurs de la p 38 et leurs procedes d'utilisation
JPWO2005094823A1 (ja) * 2004-03-30 2007-08-16 協和醗酵工業株式会社 Ｆｌｔ−３阻害剤

Also Published As

Publication number Publication date
EP1809625A1 (fr) 2007-07-25
JP2008518901A (ja) 2008-06-05
ZA200702317B (en) 2008-09-25
KR20070058689A (ko) 2007-06-08
AR051753A1 (es) 2007-02-07
TW200614990A (en) 2006-05-16
RU2007114112A (ru) 2008-12-10
IL182096A0 (en) 2007-07-24
WO2006048745A1 (fr) 2006-05-11
BRPI0517921A (pt) 2008-10-21
CN101044138A (zh) 2007-09-26
AU2005300311A1 (en) 2006-05-11
NO20072747L (no) 2007-07-31
MX2007003603A (es) 2007-05-21

Similar Documents

Publication Publication Date Title
CA2586176A1 (fr) Methodes de preparation de composes d'indazole
CN101094836A (zh) 制备吲唑化合物的方法
US7232910B2 (en) Methods of preparing indazole compounds
TWI658042B (zh) 雜環化合物的合成
CA2698245C (fr) Procede et intermediaires de preparation d'inhibiteurs de l'integrase
CN109678791B (zh) 1-(2,4-二氟苯)-2,2-二氟-2-(5-取代吡啶-2-基)乙酮及制备方法
US20070203196A1 (en) Methods of preparing indazole compounds
KR20180038460A (ko) 세포독성 벤조다이아제핀 유도체의 제조 방법
EP4249077A1 (fr) Nouveau sel d'acridinium et son procédé de production
AP1299A (en) Process for the production of quinazolines.
JP2015044856A (ja) ビフェニルイミダゾール化合物の調製方法
JP4656604B2 (ja) イノシン誘導体及びその製造方法
WO2008074474A1 (fr) 4-hydroxypyridines substituées
WO2016004899A1 (fr) Procédé de préparation de composés hétérocycliques tétracycliques
AU2005300241A2 (en) Methods for preparing indazole compounds
JP7315805B1 (ja) 単環ピリジン誘導体の合成中間体の製造方法
JP2009508898A (ja) １’−ヒドロキシ−２’−置換シクロヘキシルアゼチジン−２−オン化合物の調製方法
EP2163544A1 (fr) Méthodes de préparation de composés d' indazole
WO2014126954A1 (fr) Synthèse régiosélective de pyrimidines substituées
JP2023099776A (ja) 単環ピリジン誘導体の合成中間体の製造方法
CN112135820A (zh) 制备二氨基嘧啶衍生物或其酸加成盐的新方法
JPH0812670A (ja) 新規なピロリジン誘導体
CA2584617A1 (fr) Procede servant a produire un derive de benzo[c]phenanthridine
JP2007055960A (ja) １−デオキシガラクトノジリマイシンの製造方法、合成中間体およびその製造方法
JPWO2003042189A1 (ja) １−ｈ−１，２，４−トリアゾール−３−カルボン酸エステルの製造法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued